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Abstract
Drug perturbations of human cells lead to complex responses upon target binding. One of the known mechanisms is a
(positive or negative) feedback loop that adjusts the expression level of the respective target protein. To quantify this
mechanism systems-wide in an unbiased way, drug-induced differential expression of drug target mRNA was examined in
three cell lines using the Connectivity Map. To overcome various biases in this valuable resource, we have developed a
computational normalization and scoring procedure that is applicable to gene expression recording upon heterogeneous
drug treatments. In 1290 drug-target relations, corresponding to 466 drugs acting on 167 drug targets studied, 8% of the
targets are subject to regulation at the mRNA level. We confirmed systematically that in particular G-protein coupled
receptors, when serving as known targets, are regulated upon drug treatment. We further newly identified drug-induced
differential regulation of Lanosterol 14-alpha demethylase, Endoplasmin, DNA topoisomerase 2-alpha and Calmodulin 1.
The feedback regulation in these and other targets is likely to be relevant for the success or failure of the molecular
intervention.
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Introduction
For the future development of new drugs, the understanding of
their mechanisms of action is vital. To tackle this in a large-scale,
systemic way, the Connectivity Map (CMap) consortium studied
the effects of 1309 bioactive small molecules including more than
800 marketed drugs on genome-wide gene expression in four
cultured human cells, [1] (http://www.broadinstitute.org/cmap/).
Although drugs can perturb biological systems by interacting with
different types of biomolecules [2], analysis of successful drugs has
shown that generally they bind and alter the activity of proteins (so
called drug targets). The monitoring of genome-wide gene
expression is likely to reveal insights into the action of drugs and
the prediction of additional drug targets [1,3].
One important aspect of a good target is its reliability and
vulnerability over long periods. Biological systems are robust in a
way that they restore the perturbations caused by drug treatments.
Many drug targets thought to be suitable for therapeutic purposes
turn outtobe less effectivethanexpected oraccountforadverseside
effects [4]. Overcoming biological robustness, maintained through
positiveornegative feedbackloopsofthedrug targetproteins,might
be a key factor for success of the intended therapeutic usage of drugs
[4,5]. The genome-wide transcriptional profiling using microarrays
[1] should enable us to specifically monitor the expression changes
of drug targets induced by their inhibitors or activators. The
essential data required for this data integration are provided by i)
STITCH: a drug-target relations resource [6] and ii) the
Connectivity Map (CMap) which contains genome-wide expression
profiles of cells treated with small-molecules [1].
STITCH [6] is a repository merging multiple sources of
protein-chemical interactions providing ‘actions’ (inhibition/
activation) for 81% of the human chemical-protein interactions.
Of those, 1290 drug-target interactions are present in the CMap
comprising the actions of 466 drugs on 167 drug targets.
CMap is a searchable database of gene expression profiles [1]
that builds on the success of gene expression profiles from diverse
chemical compounds in predicting the toxicity and/or mechanism
of action of a drug [7,8]. CMap data have been already used to
create a human drug-drug and disease-drug network [9,10]. The
similarity of gene expression profiles recorded for unrelated stimuli
in cells grown at the same time (also called batch effect) is a
phenomenon known for microarray studies that needs to be
overcome [11]. In order to remedy the batch effect problem in
CMap and to make CMap amendable to various large scale
studies, Iorio et al. proposed to construct a ‘Prototype List’ of the
drug by merging its experiments from cell lines, batches,
concentrations and microarray platforms [9]. As the signal to
noise ratio can still be further improved, we implement here a
novel protocol with filtering and normalization steps in order to
utilize CMap for the elucidation of drug-induced feedback
mechanisms.
Results/Discussion
Data filtering and expression profile scoring
We obtained reliable expression differences of drug targets by
filtering and normalizing the gene expression profiles (Figure 1). In
CMap, microarray experiments were collected from four cell lines
treated with 1309 small molecules at different ranges of
concentrations and only partially with replicates. We performed
several filtering and normalization steps leaving a total of 1144
perturbations for further processing (Figure 1). After pre-
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profiles was mean centered using the average of all drug
perturbation experiments in the corresponding batch rather than
using its biological controls. We calculated pair-wise drug-induced
gene expression profile similarity (DIPS) scores using Gene set
enrichment analysis (GSEA, [12] with a similar methodology as
described in Iorio et al. [9], see Materials and Methods). In total,
4,349,432 DIPS scores were calculated between all drug pairs in
three cell lines, that we used to compare gene-expression profiles of
pairs of drugs.
Background estimates and data normalization
To reveal systematic biases, the DIPS scores of drug-induced
gene expression profiles using biological controls were classified
into four drug and batch categories (Figure 2A). The DIPS scores
between different drugs in the same batch are significantly higher
than between different drugs from different batches, implying a
considerable batch effect as has already been hinted at in the
original CMap publication [1] (Figure 2A, Label 3). Still,
characteristic drug features are reflected in the gene expression
profiles, i.e. the DIPS scores between the same drugs (Figure 2A,
Blue and Red) are significantly higher than between different
drugs from different batches (Figure 2A, Grey) (t-test p-values
,2.2610
216).
We utilized the large number of treatments to infer the
background gene expression (by mean-centering) instead of the
few biological controls provided by CMap, in order to eliminate
the batch effect. In this way, also common (e.g. stress) responses
will be down-weighted to reveal the characteristic expression
response of each chemical perturbation.
After this normalization the batch effect was largely eliminated
and the data reflect the characteristic features of drug perturba-
tions better. The DIPS scores between different drugs from the
same batch are no longer higher than between different drugs
from different batches (Figure 2A, Label 3). Additionally, the DIPS
scores between the same drugs from different batches (Figure 2A,
Red) are higher than the between different drugs from the same
batch (Figure 2A, Yellow), revealing the concordance of drug-
induced gene expression profiles across batches (t-test p-
values,2.2610
216). Same conclusions were also derived from
the distributions of Pearson correlations for drug-induced gene
expression profiles across four drug/batch categories (Figure S1).
Assessment of the drug-induced gene expression profile
similarity score
We prove the integrity and reliability of the homogeneous gene
expression profiles constructed with mean centering, by employing
benchmark sets representing different features of drugs such as
chemical structure similarity and shared Anatomical Therapeutic
Chemical (ATC) classification of the World Health Organization
(WHO) [13]. Chemical structural similarity is an indicator of
shared drug targets and mechanism of action [14–16]. It is
reported that high chemical similarity (i.e. with Tanimoto 2D
coefficients .0.85) tends to result in similar biological responses
[17]. The ATC classification is based on both the therapeutic and
chemical properties of the drug also referred to as the drug mode
of action. Thus, we expect that pairs of drugs with high structural
similarity or shared ATC classification result in similar gene
expression profiles.
Benchmarking shows that the DIPS scores calculated using the
mean-centered procedure are clearly superior to the method
proposed by Iorio et al. (Figure 2B). The area under the Receiver
operator characteristic (ROC) curve (AUC) for the combined
DIPS scores for 989 drugs (average over three cell lines), are higher
both when using chemical similarity (Tanimoto 2D coefficient
.0.8) and the 4
th level of the available ATC code shared between
drug pairs (Figure S2). This confirms that the mean-centered data
reflect the specific response after drug perturbation better than the
treatment-control comparisons that were used previously [9].
Finally, the drug induced gene expression profiles were found to
be concordant across cell lines (Figure S3). Although only cancer
cell lines were used in CMap, the procedure proposed here should
be applicable to drug perturbation profiles across multiple tissues
and even organ systems.
Differential expression of drug-induced drug targets
Integrating 4849 CMap arrays with 40,656 drug target
relations from STITCH resulted in a set of 1,290 drug-target
relations for which a genome-wide cellular response is available.
We found that thirteen out of 167 distinct drug targets in this set
(8%; 86 drug target relations) are subjected to significant
differential expression upon drug treatment (Figure 3) by
comparing the drug-induced expression changes of the drug
target against all other treatments present in CMap (see
methods). We found supporting evidence in the literature for
seven out of thirteen (q-value ,0.05) significant differential
regulations of drug targets shown in Figure 3, confirming the
rationale and predictive power of our systematic approach. For
the remaining six targets we can predict a hitherto unknown
drug-induced differential regulation.
The identified, differentially regulated drug targets are enriched
in G-protein coupled receptors (GPCRs) (Figure S4), in agreement
with previous reports that members of the GPCR family are
generally regulated by several mechanisms including receptor
desensitization, endocytosis at the protein level and regulation of
the cellular receptor content [18,19]. In the three cancer cell lines
used, we observe agonist-induced down-regulation of GPCR
mRNAs for beta-2 adrenergic receptor (ADRB2), prostaglandin
E2 receptor subtype EP2 and prostaglandin E4 receptor subtype
EP4 (Figure 3, Genes 3,4,12), which were previously reported in
DDT1 MF-2 smooth muscle cells (ADRB2) and 293-EBNA
human embryonic kidney cells (prostaglandin E2/E4 receptor
Author Summary
Many drug targets thought to be suitable for therapeutic
purposes are subjected to positive or negative feedback
loops upon chemical perturbations which might even
account for the development of drug tolerance. In this
study, we carried out the first systematic analysis of drug-
induced differential expression of drug targets using the
Connectivity Map, a resource that contains the genome-
wide expression profiles of 1309 bioactive small molecules
performed on four cultured human cells. The main
obstacle in analyzing such a large set of profiles is the
non-biological experimental variation across batches. We
overcame this by developing a pipeline for strict filtering
and state-of-the-art normalization and were able to utilize
the Connectivity Map for assessing the drug-induced
differential regulation of drug targets. Using the normal-
ized data, we found that at least 8% of the drug-induced
drug targets studied are differentially regulated in three
cell lines; some of these confirm previous observations in
other cell lines. Our work not only quantifies the amount of
target expression feedback loops in three human cell lines,
but also identifies so far unknown drug-induced target
expression changes; some of them can be linked to the
development of drug tolerance in patients.
Feedback Loops of Drug-Targets
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similar feedback loops in a wide variety of cell types. However, we
cannot rule out that cross-regulation among signaling pathways
may be responsible for the regulation of GPCR mRNAs as it has
been described before [22]. For example, it has been shown that a
beta adrenergic mRNA-binding protein, ELAV-like protein 1
(ELAVL1) can be induced by ADRB2 agonist or elevated levels of
cyclic adenosine monophosphate (cAMP) [22,23] and destabilizes
ADRB2 mRNA. The ELAVL1 protein binds to GPCR mRNAs
and recognizes a cognate sequence located at the 39-UTR of
ADRB2, proteinase-activated receptor and M2, M3 muscarinic
acetylcholine receptor mRNAs [24,25]. Therefore cAMP provides
cross-talk among GPCR regulatory networks. However, it is
shown that intracellular cAMP accumulation is not the only factor
contributing to the reduction of ADRB2 mRNA levels [20].
Moreover, we find that GPCR-targeting drugs regulate the
transcription of their specific targets (Figure S5). We conclude
that in addition to the cross-regulation of G-protein signaling
pathways drug target-specific feedback loops are also responsible
for the regulation of drug target mRNAs.
In addition to cross-regulation of multiple drugs through the
same signaling pathways, promiscuous drugs targeting multiple
proteins may cause complex regulatory networks. In order to
explore the cross-regulation of drug targets induced by a
promiscuous drug, we searched and found that 259 out of 466
total drugs are multi-target drugs and 4 of these drugs act on
Figure 1. Workflow for the pipeline used to normalize and analyze Connectivity Map microarray experiments. The reliability of drug-
induced gene expression profile similarity scores (DIPS scores) were evaluated using independent drug features as benchmark. Using the processed
data, differential regulation of drug-induced drug targets was investigated.
doi:10.1371/journal.pcbi.1000925.g001
Feedback Loops of Drug-Targets
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For example, Podophyllotoxin used in various chemotherapies is
known to target both tubulin beta 2C and DNA topoisomerase 2-
alpha. The tubulin beta 2C and DNA topoisomerase 2-alpha
mRNAs are both down-regulated upon drug treatment in three
cell lines (Figure 3, Genes 8,13). Tubulin beta 2C inhibitors induce
microtubule depolymerization that leads to the specific down-
regulation of tubulin beta 2C mRNAs preventing the translational
synthesis and thus the further accumulation of abundant tubulin
monomers [26]. Moreover, we found that DNA topoisomerase 2-
alpha mRNAs are not down-regulated upon treatment of other
tubulin inhibitors (Figure S5). Therefore, we conclude that
feedback loops of tubulin beta 2C and DNA topoisomerase 2-
alpha are not cross-regulated. Two other examples of multi-target
drugs are vorinostat used for the treatment of cutaneous T cell
lymphoma and trichostatin A that serves as an antifungal
antibiotic. Vorinostat and trichostatin A are considered to be
nonspecific histone deacetylase inhibitors. These drugs lead to the
up-regulation of histone deacetylase 3 (HDAC3) and down-
regulation of histone deacetylase 7 (HDAC7) (Figure 3, Genes 1,5).
In this case it is unclear whether there is cross-regulation, although
HDAC7 siRNA experiments failed to induce the up-regulation of
HDAC3 mRNAs [27], a result that is disfavoring the cross-
regulation.
Figure 2. Analysis of systematic biases and benchmarking with independent features of chemicals. (A) Distributions of the DIPS scores
for the pair-wise comparisons of gene expression profiles constructed using biological controls and mean centering as background across four drug/
batch categories: i) both profiles are from the same drug and the same batch (Blue), ii) the same drug from different batches (Red), iii) different drugs
from the same batch (Yellow) and iv) different drugs from different batches (Grey) (B) ROC curves are used to assess the performance of the DIPS
score (blue line) and provide a comparison with the method described in Iorio et al. (red line) [9]. Area under the curve values for each ROC curve:
Chemical structural similarity: AUC (DIPS=0.028 for FPR,0.1) and (AUC Iorio et al.=0.016 for FPR,0.1). For 4
th level ATC sharing, the AUC
(DIPS=0.016 for FPR,0.1) and (AUC Iorio et al.=0.009 for FPR,0.1)(Refer to Figure S2 for the complete ROC plots.).
doi:10.1371/journal.pcbi.1000925.g002
Feedback Loops of Drug-Targets
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cell lines or tissues, we also identified new cases of drug-induced
expression regulation of drug targets. The significant novel
findings are the inhibitor-induced down-regulation of calmodulin
1, DNA topoisomerase 2-alpha and up-regulation of endoplasmin,
lanosterol 14-alpha demethylase and cAMP-specific phosphodies-
terase 4D (Figure 3, Genes 9,8,2,7,10). Lanosterol 14-alpha
demethylase is actually an off-target of antifungal drugs that bind
the mammalian version with lower affinity than the fungal
lanosterol 14-alpha demethylase. Probably, the up-regulation of
the mammalian lanosterol 14-alpha demethylase compensates for
the undesired inhibition and modulates the adverse effects. On the
contrary, we observed a feedback loop that accelerates the down
regulation of calmodulin 1 mRNA induced by calmodulin
inhibitors. Calmodulin targeting drugs can provide a rapid and
effective therapeutic effect, while at the same time small variations
of drug concentrations can increase adverse effects. Therefore, it
would be interesting to study further the functional effects upon
target inhibition of lanosterol 14-alpha demethylase, endoplasmin
and calmodulin 1 to elucidate the roles of feedback loops in drug
mode of action and adverse effects.
Drug-induced target regulation might be implicated in tolerance
development and thus identifying potential target regulation
should be an integral part of drug discovery to prevent failures
in later stages of clinical trials. For example, we have observed the
inhibitor-induced up-regulation of ADRB2 and thymidylate
synthetase (TYMS)(Figure 3, Genes 3,11) [28]. TYMS is an
essential enzyme for DNA replication/repair and an important
drug target in cancerous cells. Indeed, it has been shown that
inhibitor-induced TYMS over-expression obstructs the clinical
efficiency by inducing tumor drug resistance [29]. In addition to
over-expression, down-regulation of drug targets upon agonist
treatment may also cause treatment tolerance as observed for
ADRB2 long-acting agonist treatment. ADRB2 is a therapeutic
target activated to treat the symptoms of asthma. We observe the
agonist-induced up-regulation of ADRB2 and already in 2005, the
FDA warned patients that ADRB2 might be down-regulated
(desensitization) and be unresponsive for asthma treatment due to
long-acting agonist exposure [20,30]. Thus, robustness in
biological systems could prevent the applicability of the long-term
treatments via positive/negative feedback loops of the drug target
affecting the clinical efficiency of drugs in trial and on the market.
Drug-induced regulation of drug targets can thus be linked to
tolerance development, which restricts the efficiency of clinical
treatments where the drug concentration is limited to avoid an
excess of adverse drug reactions.
Taken together, we have identified drug-induced differential
regulation of drug targets. Due to the limited signal to noise ratio
in the data at hand, the identified 8% of all drug targets that show
feedback loops has to be seen as a lower limit, i.e. target-regulation
Figure 3. Drug-induced differentially regulated drug targets. Anova is used to assess the significance of the differential expression of drug-
induced drug targets against the mRNA changes of the same gene in the population of heterogeneous drug treatments from CMap. The genes are
mainly ordered based on their q-values as provided in Table S1. In the scatter plots, inhibitors/activators are labeled in red/green respectively and
grey represents all other treatments present in CMap.
doi:10.1371/journal.pcbi.1000925.g003
Feedback Loops of Drug-Targets
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taken into account during drug development.
Materials and Methods
Data source
Connectivity Map (CMap, build 02) contains 6100 gene
expression profiles of 4 cell lines treated with 1309 distinct small
molecules. Data from Connectivity Map was downloaded from the
CMAP main website (http://www.broadinstitute.org/cmap/). On
this data set, filtering was performed in multiple steps as follows:
Treatment instances (i.e. one treatment versus vehicle control pair)
from three cell lines (HL60, Human promyelocytic leukemia cell
line; MCF7, Human breast adenocarcinoma cell line; PC3,
Human prostate cancer cell line) were taken into consideration.
Only the treatment instances from the production batches
containing over twenty-five treatments in HT_HG-U133A
platform were selected (with the exception of HL60 cell line
where HG-U133A microarray platform was also included.) Lastly,
for each cell line, the highest concentration of treatments was
selected discarding lower concentration treatments. Figure 1 shows
the number of treatment instances used in this study before and
after filtering. In total, we analyze here a total of 4849 treatment
instances in three cell lines corresponding to 1144 small molecules,
in which 989 of them are tested in each cell line.
Data pre-processing
Treatment arrays were grouped based on the cell line. For the
HL60 cell line, treatments from different microarray platforms
were further classified in separate groups. Each group was pre-
processed separately using RMA [31]. Vehicle controls from
CMap were discarded and for each batch individual probes of
each treatment were mean centered to calculate the average
difference values within the batch. To construct a unique gene
expression profile of a small molecule for each cell line, replicate
treatments were merged into one averaging their probe sets values.
For the HL60 cell line, profiles from multiple microarray platforms
were not merged because there was not any experiment with the
same drug treatment from different microarray platforms.
The probe sets for the small-molecule gene expression profile
were ranked based on both their detection call and their average
log-signal difference value for the probe set [32]. Detection calls
were assigned on the probe sets for individual experiments. A
probe set was labeled to be ‘Present in a cell line’ if the detection
call algorithm had assigned ‘present’ for that probe set in at least
half of the drug treatment experiments in that corresponding cell
line. Ranking was performed in two steps. First, for probe sets
assigned to be ‘Absent’ in tested cell line, the average difference
was set to 0. Next, all probe sets were ranked in the descending
order of their average difference. Last, to get the final ranked gene
expression profile, the probe sets, which were set to 0, were sub-
sorted based on their initial average difference.
Pairwise similarity score of drugs
Pairwise similarity scores between small-molecule gene expres-
sion profiles were calculated using a similar method presented in
Iorio et al. [9]. An optimal signature was created for each gene
expression profile of the drug. This optimal signature consists of
the top 250 and bottom 250 ranked probe sets in the gene
expression profile. These probe sets are the characteristic cellular
response of the drug treatment that might be specific to cell line.
To get the similarity score between drug X and Y: The down-
regulated and up-regulated features of the optimal signature from
drug X were searched within the weighted gene expression profile
of drug Y. In same respect, top and down regulated signature
genes of drug Y were also searched within the weighted gene
expression profile of Drug X. To quantify a similarity score, gene
set enrichment analysis (GSEA) based on Kolmogorov-Smirnov
statistics were used [12]. All results obtained through GSEA were
averaged to obtain the final score of gene expression profile
comparison for a drug pair in a specific cell line.
As we might have up to three expression profiles of the small-
molecule treatment from three cell lines, it is possible to compare
gene expression profiles of the drug pairs within and between cell
lines. In this study, drug-induced gene expression profile similarity
scores were only calculated within cell lines. To increase reliability
of DIPS score, a combined similarity score was calculated as the
average of the similarity scores for the drug pair from multiple cell
lines.
Drug target expression changes
A drug can act on the protein if the protein is physically present
in the cell. A drug target was considered to be ‘expressed’ and
present if the detection call algorithm [32] reports it as such for
one-tenth of the treatment experiments in the cell line. Drug
targets that were not expressed and labeled ‘‘absent’’ were
excluded. Drug target information was gathered from STITCH
2.0 including actions of the interaction. These interactions were
labeled as ‘activation’ or ‘inhibition’ (including ‘binding’). To
minimize indirect associations, only the drug-target relations from
experimental and curated database annotations over 0.7 threshold
were taken into consideration. For the significant cases of drug-
induced differential regulation of drug targets, ‘binding’ associa-
tions are manually corrected and the results are re-calculated.
Drug-induced gene-expression of a drug target used in this
context indicates the expression change of the target mRNA upon
drug treatment acting on the corresponding target. Significance of
the expression changes of the drug target were evaluated by
comparing the drug-induced expression changes of target mRNAs
with the expression changes of the target upon all other chemical
treatments present in CMap. ANOVA was used to assess the
significance for the expressional change of individual drug targets
from multiple cell lines. Table S1 provides the t-test results for the
expression changes of drug targets for individual cell lines.
Supporting Information
Figure S1 Histograms comparing the distributions of pearson
correlations for drug induced gene expression profiles across four
drug/batch categories using two different pre-processing pipelines.
Main difference of these two pipelines is based on the selection of
control as background; biological controls or mean centering. In
the case of using biological controls, the distribution of pearson
correlations between different drugs in the same batch are
significantly higher than between different drugs from different
batches, indicating the batch effect within the data.
Found at: doi:10.1371/journal.pcbi.1000925.s001 (0.17 MB TIF)
Figure S2 Same as Figure 2B of the main paper, complete ROC
plots for DIPS score benchmarking with independent features of
chemicals. (A) The AUC of DIPS and Iorio et al. are 0.70 and 0.62
respectively with the binary classification of tanimoto score over
0.8. (B) Shared 4th level of Anatomical Therapeutic Chemical
classification is used as binary classifier for the drugs with available
ATC classification. AUC of DIPS and Iorio et al. are 0.63 and
0.55, respectively.
Found at: doi:10.1371/journal.pcbi.1000925.s002 (0.40 MB
TIF)
Feedback Loops of Drug-Targets
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profile similarity scores for drug-drug pairs across four drug/cell
line categories. To gain a comprehensive picture of drug
concordance across cell lines, we evaluated whether the similarity
scores are driven by cell-line specific gene expression. For pairwise
comparison of profiles from different cell lines, drug treatments
from multiple cell lines were merged into one matrix where only
the ‘Present’ probe sets for three cell lines were preserved in the
matrix. The DIPS scores on the category of the same drug from
different cell lines (D+/C2) are significantly higher than the scores
within the category of different drugs from the same cell line
(D2/C+) (t-test p-value ,2.2610216) meaning that the drug
response is generally concordant across cell lines.
Found at: doi:10.1371/journal.pcbi.1000925.s003 (0.34 MB TIF)
Figure S4 Distribution of molecular functions of differentially
regulated drug-targets (p-value ,0.05) compared to molecular
functions of all other targets. Drug target classification is based on
the categorization described in ChEMBL with few changes. For
instance, for a more detail categorization, the lyase, hydrolase,
oxidoreductase and transferase activities were included. If a drug
target is identified within multiple categories, the order of the
categories introduced was used to choose the first category as the
main category to annotate the drug target. (GO:0004930: G-
protein coupled receptor activity, GO:0004879: Ligand-depen-
dent nuclear receptor activity, GO:0005216: Ion channel activity,
GO:0005215: Transporter activity, GO:0004112: Cyclic-nucleo-
tide phosphodiesterase activity, GO:0005198: Structural molecule
activity, GO:0003700: Transcription factor activity, GO:0016301:
Kinase activity, GO:0008233: Peptidase activity, GO:0016829:
Lyase activity)
Found at: doi:10.1371/journal.pcbi.1000925.s004 (0.97 MB
TIF)
Figure S5 Differentially regulated GPCRs and topoisomerase II
of Figure 3 were tested by other GPCR antagonist/agonists and
tubulin inhibitors, respectively. The GPCR antagonists/agonists
were selected based on the ‘present’ call for their targets in the
tested cell line (see Materials and Methods). Both drug-induced
receptor-specific response and cross-regulation among signaling
pathways may be responsible for the differential regulation of drug
targets.
Found at: doi:10.1371/journal.pcbi.1000925.s005 (0.42 MB
TIF)
Table S1 Complete list of statistical tests for the differential
regulations of drug-targets. The average difference values for the
drug-induced drug-targets are tested against the mRNA changes
of the same gene in the population of heterogeneous drug
treatments from CMap. Anova is used to assess the significance of
the differential expression of drug-induced drug targets in multiple
and specific cell lines, respectively. This excel sheet contains the
name of the drug-targets with its evaluation in multiple cell lines.
Only the drug-targets whose detection call are ‘Present’ in more
than one-tenth of the experiments in specified cell line, are
pursued for the analysis of differential gene-expression of drug-
targets. If the detection call does not specify the required criteria,
the column of a drug-target for that cell line is left blank. The
q-values reported here are calculated using the FDR correction
algorithm.
Found at: doi:10.1371/journal.pcbi.1000925.s006 (0.10 MB
XLS)
Acknowledgments
We thank Wolfgang Huber, John P. Overington and the members of the
Bork group for helpful discussions.
Author Contributions
Conceived and designed the experiments: MI MK VvN PB. Analyzed the
data: MI VvN. Contributed reagents/materials/analysis tools: MC LJJ.
Wrote the paper: MI MC VvN PB.
References
1. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, et al. (2006) The
Connectivity Map: using gene-expression signatures to connect small molecules,
genes, and disease. Science 313: 1929–1935.
2. Hopkins AL, Groom CR (2002) The druggable genome. Nat Rev Drug Discov
1: 727–730.
3. Drews J (1996) Genomic sciences and the medicine of tomorrow. Nat Biotechnol
14: 1516–1518.
4. Kitano H (2007) A robustness-based approach to systems-oriented drug design.
Nat Rev Drug Discov 6: 202–210.
5. Stelling J, Sauer U, Szallasi Z, Doyle FJ, 3rd, Doyle J (2004) Robustness of
cellular functions. Cell 118: 675–685.
6. Kuhn M, Szklarczyk D, Franceschini A, Campillos M, von Mering C, et al.
(2010) STITCH 2: an interaction network database for small molecules and
proteins. Nucleic Acids Res 38: D552–556.
7. Gunther EC, Stone DJ, Gerwien RW, Bento P, Heyes MP (2003) Prediction of
clinical drug efficacy by classification of drug-induced genomic expression
profiles in vitro. Proc Natl Acad Sci U S A 100: 9608–9613.
8. Hughes TR, Marton MJ, Jones AR, Roberts CJ, Stoughton R, et al. (2000)
Functional discovery via a compendium of expression profiles. Cell 102:
109–126.
9. Iorio F, Tagliaferri R, di Bernardo D (2009) Identifying network of drug mode of
action by gene expression profiling. J Comput Biol 16: 241–251.
10. Hu G, Agarwal P (2009) Human disease-drug network based on genomic
expression profiles. PLoS One 4: e6536.
11. Lander ES (1999) Array of hope. Nat Genet 21: 3–4.
12. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005)
Gene set enrichment analysis: a knowledge-based approach for interpreting
genome-wide expression profiles. Proc Natl Acad Sci U S A 102: 15545–15550.
13. Andersen AH, Hvidberg E (1981) [New classification of drugs: ATC-code
introduced]. Sygeplejersken 81: 24–26.
14. Kuhn M, Campillos M, Gonzalez P, Jensen LJ, Bork P (2008) Large-scale
prediction of drug-target relationships. FEBS Lett 582: 1283–1290.
15. Campillos M, Kuhn M, Gavin AC, Jensen LJ, Bork P (2008) Drug target
identification using side-effect similarity. Science 321: 263–266.
16. Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, et al. (2009) Predicting new
molecular targets for known drugs. Nature 462: 175–181.
17. Matter H (1997) Selecting optimally diverse compounds from structure
databases: a validation study of two-dimensional and three-dimensional
molecular descriptors. J Med Chem 40: 1219–1229.
18. Lohse M (1993) Molecular mechanisms of membrane receptor desensitization.
Biochim Biophys Acta 1179: 171–188.
19. Eason MG, Kurose H, Holt BD, Raymond JR, Liggett SB (1992) Simultaneous
coupling of alpha 2-adrenergic receptors to two G-proteins with opposing effects.
Subtype-selective coupling of alpha 2C10, alpha 2C4, and alpha 2C2 adrenergic
receptors to Gi and Gs. J Biol Chem 267: 15795–15801.
20. Hadcock JR, Malbon CC (1988) Down-regulation of beta-adrenergic receptors:
agonist-induced reduction in receptor mRNA levels. Proc Natl Acad Sci U S A
85: 5021–5025.
21. Desai S, April H, Nwaneshiudu C, Ashby B (2000) Comparison of agonist-
induced internalization of the human EP2 and EP4 prostaglandin receptors: role
of the carboxyl terminus in EP4 receptor sequestration. Mol Pharmacol 58:
1279–1286.
22. Morris AJ, Malbon CC (1999) Physiological regulation of G protein-linked
signaling. Physiol Rev 79: 1373–1430.
23. Hadcock JR, Ros M, Malbon CC (1989) Agonist regulation of beta-adrenergic
receptor mRNA. Analysis in S49 mouse lymphoma mutants. J Biol Chem 264:
13956–13961.
24. Danner S, Frank M, Lohse MJ (1998) Agonist regulation of human beta2-
adrenergic receptor mRNA stability occurs via a specific AU-rich element. J Biol
Chem 273: 3223–3229.
25. Tholanikunnel BG, Granneman JG, Malbon CC (1995) The M(r) 35,000 beta-
adrenergic receptor mRNA-binding protein binds transcripts of G-protein-
linked receptors which undergo agonist-induced destabilization. J Biol Chem
270: 12787–12793.
Feedback Loops of Drug-Targets
PLoS Computational Biology | www.ploscompbiol.org 7 September 2010 | Volume 6 | Issue 9 | e100092526. Caron JM, Jones AL, Kirschner MW (1985) Autoregulation of tubulin synthesis
in hepatocytes and fibroblasts. J Cell Biol 101: 1763–1772.
27. Hemmatazad H, Rodrigues HM, Maurer B, Brentano F, Pileckyte M, et al.
(2009) Histone deacetylase 7, a potential target for the antifibrotic treatment of
systemic sclerosis. Arthritis Rheum 60: 1519–1529.
28. MacEwan DJ, Milligan G (1996) Inverse agonist-induced up-regulation of the
human beta2-adrenoceptor in transfected neuroblastoma X glioma hybrid cells.
Mol Pharmacol 50: 1479–1486.
29. Libra M, Navolanic PM, Talamini R, Cecchin E, Sartor F, et al. (2004)
Thymidylate synthetase mRNA levels are increased in liver metastases of
colorectal cancer patients resistant to fluoropyrimidine-based chemotherapy.
BMC Cancer 4: 11.
30. Vathenen AS, Knox AJ, Higgins BG, Britton JR, Tattersfield AE (1988)
Rebound increase in bronchial responsiveness after treatment with inhaled
terbutaline. Lancet 1: 554–558.
31. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, et al. (2003) Summaries
of Affymetrix GeneChip probe level data. Nucleic Acids Res 31: e15.
32. Liu WM, Mei R, Di X, Ryder TB, Hubbell E, et al. (2002) Analysis of high
density expression microarrays with signed-rank call algorithms. Bioinformatics
18: 1593–1599.
Feedback Loops of Drug-Targets
PLoS Computational Biology | www.ploscompbiol.org 8 September 2010 | Volume 6 | Issue 9 | e1000925